Proton Therapy Pediatric denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for proton therapy pediatric are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Applies Step Therapy to Pediatric Proton Therapy

Step-therapy requirements for radiation services are less common than for medications, but they occur. In the context of pediatric proton therapy, a step-therapy denial typically means Aetna's policy requires documentation that conventional photon-based radiation was considered, attempted, or determined to be clinically inadequate before proton therapy will be authorized. Some policies frame this as a "photon-first" or "least-costly-alternative" requirement. The denial signals that the authorization request did not include sufficient documentation that the step-therapy pathway was followed or that an exception is clinically justified.

## Why This Denial Is Appealable

Step-therapy requirements are subject to override when adherence would be clinically harmful or when the required prior step is contraindicated for this specific patient. For pediatric patients, there are well-recognized clinical scenarios in which proceeding with conventional radiation before attempting proton therapy would expose a child to avoidable harm — particularly when tumor proximity to critical developing structures makes the dosimetric difference between modalities clinically significant. The appeal must document why the step-therapy pathway is not appropriate for this child, not merely assert a general preference for proton therapy.

## Federal Appeal Framework

• Internal appeal: File within 180 days of denial. Request the precise step-therapy requirement that was not satisfied and the policy provision that imposes it.
• Step-therapy override laws: Many states have enacted laws requiring insurers to grant step-therapy exceptions when adherence would be harmful, the required treatment is contraindicated, or the patient previously failed the required step. Identify whether your state's law applies.
• External review (ACA §2719): After internal denial, an IRO can assess whether the step-therapy requirement was appropriately applied and whether an exception is warranted.
• ERISA §503: For employer-sponsored plans, the plan must disclose the criteria for step-therapy exceptions.
• Expedited review: Request if the step-therapy requirement is delaying time-sensitive treatment.
• External review window: Initiate within four months of the final internal denial.

## Documentation to Gather

• Clinical rationale for bypassing the step: The treating radiation oncologist's detailed explanation of why conventional photon radiation is not an appropriate first step for this specific pediatric patient — tied to tumor location, organs at risk, and the child's developmental stage.
• Dosimetric comparison: A quantitative treatment-planning comparison demonstrating the clinical significance of the dosimetric difference between modalities for this patient.
• Prior treatment history: Any prior radiation or oncologic treatment that may have already consumed the "step" the plan is requiring.
• Diagnosis and staging: Complete oncologic workup.
• State step-therapy override law: If applicable, cite the state law and its exception criteria, then document how this patient meets each exception.

## Criteria-Mapping Structure

Obtain Aetna's step-therapy policy for proton beam therapy and identify every condition under which the step-therapy requirement can be bypassed. For each exception criterion, provide the specific chart fact that satisfies it. If the policy does not list exceptions, the appeal should assert the clinical-harm argument directly and request that the plan apply its exception process. A well-structured appeal that addresses the step-therapy requirement head-on — rather than restating the general case for proton therapy — is most likely to succeed.